This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: Erythropoietin, a hormone produced in the kidney, stimulates bone marrow to produce red blood cells. For over 10 years a recombinant form of erythropoietin, epoetin alfa (EPO), has been used in neonates to treat anemia of prematurity. However, because this treatment often requires daily subcutaneous injections, pain and local skin reactions may occur. In an effort to reduce discomfort caused by these daily injections, an indwelling subcutaneous catheter (Insuflon ) is sometimes used in the neonate. The Insuflon catheter can be inserted into subcutaneous tissue and remain in place for 7 days. To date, no one has published data concerning the clinical utility of the Insuflon catheter for the delivery of EPO in the premature infant. Purpose: To compare safety, efficacy, and nurse satisfaction of the Insuflon catheter with repeated subcutaneous injections of EPO in neonates with anemia of prematurity. Methods: This is a prospective, randomized study. We will measure nurse satisfaction and safety of the Insuflon catheter versus standard injections using a questionnaire provided to the bedside nurse who cares for neonates requiring daily subcutaneous EPO therapy. To measure efficacy, we will document hematocrit and reticulocyte counts for these infants before and after EPO therapy.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRR1-CR-9 (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Schools of Medicine
United States
Zip Code
Levenson, Amy E; Wadwa, R Paul; Shah, Amy S et al. (2017) PCSK9 Is Increased in Youth With Type 1 Diabetes. Diabetes Care 40:e85-e87
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2017) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes :
Arslanian, Silva; El Ghormli, Laure; Bacha, Fida et al. (2017) Adiponectin, Insulin Sensitivity, ?-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY. Diabetes Care 40:85-93
Gan, Ryan W; Demoruelle, M Kristen; Deane, Kevin D et al. (2017) Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. Ann Rheum Dis 76:147-152
Nandi-Munshi, Debika; Afkarian, Maryam; Whitlock, Kathryn B et al. (2017) Vitamin D and Albuminuria in Youth with and without Type 1 Diabetes. Horm Res Paediatr 87:385-395
Liu, Edwin; Dong, Fran; Barón, Anna E et al. (2017) High Incidence of Celiac Disease in a Long-term Study of Adolescents With Susceptibility Genotypes. Gastroenterology 152:1329-1336.e1
Cree-Green, Melanie; Gupta, Abhinav; Coe, Gregory V et al. (2017) Insulin resistance in type 2 diabetes youth relates to serum free fatty acids and muscle mitochondrial dysfunction. J Diabetes Complications 31:141-148
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2017) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes :
Crume, Tessa L; Hamman, Richard F; Isom, Scott et al. (2016) Factors influencing time to case registration for youth with type 1 and type 2 diabetes: SEARCH for Diabetes in Youth Study. Ann Epidemiol 26:631-7
Marcus, M D; Wilfley, D E; El Ghormli, L et al. (2016) Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience. Pediatr Obes :

Showing the most recent 10 out of 829 publications